Reviving old antibiotics: Colistin terminology
October 25, 2013 1 Comment
Multidrug resistance is a growing health crisis and old antibiotics such as colistin are being used increasingly as a last-line therapy against infections caused by Gram-negative bacteria that are resistant to other available antibiotics. Colistin was never developed according to current regulatory standards and regional differences in approved product characteristics and labeling is confounding the appropriate clinical use of colistin worldwide. A serious problem is the confusing terminology of describing the contents of parenteral vials and corresponding doses of the administered prodrug colistin colistin methanesulfonate (CMS) that may lead to lethal dosing errors.
The experts of The Prato Polymyxin Consensus recently published a letter to the editor of Clinical Infectious Diseases that recommends a consistent global approach on reporting of colistin doses and labeling.